Anaphylaxis Campaign is pleased to announce the appointment of Simon Williams as CEO, as of 22 November 2021.   Simon succeeds Lynne Regent, who retired in August 2021 after 13 years as Chief Executive. Simon was Head of External Affairs

The Anaphylaxis Campaign, the only UK-wide charity operating solely for the growing numbers of people at risk from severe allergic reactions, has welcomed a new Ambassador to help raise awareness and create a safer environment for those with allergies. Julianne Ponan,

The May Contain Break the Stigma campaign empowers young people to speak up about their allergies and feel confident addressing them throughout their lives. The campaign features inspiring allergy advocates from TV, theatre, sport, and news. LINK TO THE HERO

Latest figures reveal that hospital admissions for anaphylactic shock in adults aged 19 and over have increased 27% since last year and risen dramatically over the last seven years. Hospital admissions for anaphylactic shock for adults increased from 3751 to

The Anaphylaxis Campaign is pleased to announce that Professor John Warner OBE, Emeritus Professor of Paediatrics, Imperial College, London and Hon.Professor University of Cape Town, South Africa, has become the new Chair of the charity’s Clinical and Scientific Advisory Panel. Now semi-retired, Professor

The Anaphylaxis Campaign, a UK charity that supports the growing number of adults and children affected by severe allergies, has today (6 May 2020) announced its new president, former vice-president David Reading OBE. On 2 April, the charity was notified

In the run-up to our annual Anaphylaxis Awareness Week (4 – 10 May), the Anaphylaxis Campaign would like to welcome our new youth ambassador Dan Kelly, founder of the ‘May Contain’ blog (Instagram @_maycontain) and podcast, who will be working with us to support and empower

The Anaphylaxis Campaign is delighted to hear about the success of Aimmune Therapeutics, Inc. in the approval of their oral immunotherapy drug, Palforzia, by the US Food and Drug Administration (FDA). This is the first oral immunotherapy drug that has

An editorial in the February edition of Clinical and Experimental Allergy (the official journal of the British Society of Allergy and Clinical Immunology) explores the current statutory guidance on the care of children with medical conditions in schools, and highlights